biopharmaceutical company

Armetheon, Inc. is a privately held biopharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis and cardiac arrhythmias. Armetheon focuses on improved therapies with the goal of increased efficacy, safety, and utility, targeting specialty markets with clearly defined regulatory pathways.

Armetheon’s two late-stage small molecule drug candidates are being investigated for use in the areas of oral anticoagulation and cardiac arrhythmia management. Armetheon’s lead candidate, tecarfarin, is being investigated for use as a Vitamin K Antagonist and is currently in Phase 3 development for the prevention and management of thrombosis. Armetheon is also developing its anti-arrhythmic drug candidate, budiodarone, for the treatment of ventricular tachycardia (VT) in patients with implantable cardioverter defibrillators (ICDs).

Press Releases

In The News

This part of our website contains archival information which should not be considered current and may no longer be considered accurate.

Our Investors

Atheneos Capital is a San Francisco Bay area-based, healthcare-focused, evergreen incubator fund dedicated to identifying and nurturing high-quality, high-risk (and potentially) game-changing healthcare companies.

AshHill is a private investment firm with a specialized focus on the biomedical sector and participating in its portfolio companies in active management roles, as well as scientific and support services. Its mission is to discover, analyze and invest in start-up, seed-stage and established companies that are working to develop medical innovations.

  • Hercules Bioventure Partners

  • Capital TEN II

  • China Development Industrial Bank (CDIB) Healthcare

  • CDIB & Partners

  • iD SoftCapital Group

  • AmKey Ventures

  • A group of Limited Partners in these funds and super angels